Clinical data challenges are hindering pharmaceutical companies' abilities to bring more drugs to the market faster. These challenges were addressed with a study commissioned by Oracle Health Sciences and conducted by Pharma Intelligence.
To begin, the survey revealed that 57 percent of the clinical researchers believe that their clinical data issues result in trial delays. In addition to trial delays, 81 percent of respondents cited data governance issues as the biggest challenge in meeting regulatory compliance which include duplicate data/inconsistent data, data quality, and data integrity/traceability.
When asked what the top three operational challenges were with their clinical trial data, 51 percent cited data completeness, 45 percent said data quality and 43 percent, data cleaning. Not surprisingly, over three-fourths of respondents cited inconsistent data and missing patient data as the most critical clinical data problems to catch in clinical trials.
To conclude, the top three risks highlighted by the research include the need for additional data reconciliation; incomplete data to determine efficacy and patient replacements.
Read the full release here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.